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Abstract:  Effects  of  the  degree  of  deacetylation  (DDA)  and  the  molecular  mass  of 
chitosan  oligosaccharides  (CTS-OS),  obtained  from  the  enzymatic  hydrolysis  of  high 
molecular weight chitosan (HMWC), on antitumor activity was explored. The DDA and 
molecular  weights  of  CTS-OS  were  determined  by  matrix-assisted  laser 
desorption/ionization-mass spectrometry (MALDI-TOF MS) analysis. The CTS-OS were 
found  to  be  a  mixture  of  mainly  dimers  (18.8%),  trimers  (24.8%),  tetramers  (24.9%), 
pentamers (17.7%), hexamers (7.1%), heptamers (3.3%), and octamers (3.4%). The CTS-OS 
were  further  fractionated  by  gel-filtration  chromatography  into  two  major  fractions: 
(1) COS,  consisting  of  glucosamine  (GlcN)n,  n  =  3–5  with  DDA  100%;  and 
(2) HOS, consisting of (GlcN)5 as the minimum residues and varying number of 
N-acetylglucosamine (GlcNAc)n, n = 1–2 with DDA about  87.5% in random order. The 
cytotoxicities, expressed as the concentration needed for 50% cell death (CC50), of CTS-OS, 
COS, and HOS against PC3 (prostate cancer cell), A549 (lung cancer cell), and HepG2 
(hepatoma  cell),  were  determined  to  be  25  g∙mL
-1,  25  g∙mL
-1,  and  50  g∙mL
-1, 
respectively. The HMWC was approximately 50% less effective than both CTS-OS and 
COS.  These  results  demonstrate  that  the  molecular  weight  and  DDA  of  chitosan 
oligosaccharides are important factors for suppressing cancer cell growth. 
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1. Introduction 
Chitin  is  the  second  most  abundant  naturally  occurred  homopolysaccharide  composed  of   
-(1,4)-linked-D-N-acetylglucosamine  (GlcNAc)  after  cellulose.  Chitosan  is  a  linear 
heteropolysaccharide  composed  of  -(1,4)-linked-D-glucosamine  (GlcN)  and  N-acetylglucosamine 
(GlcNAc),  which is  derived from chitin.  For several  decades,  the study on chitosan has  attracted 
interest  in  converting it into more soluble form  of chitosan-oligosaccharides,  hereafter  referred to   
CTS-OS, which exhibit remarkable biological activities [1–5]; they are non-toxic, biocompatible and 
biodegradable  [6],  including  antibacterial  antifungal,  antitumor  and  stimulating  immunoenhancing 
properties.  It  is  implicated  that  the  biological  activities  of  CTS-OS  significantly  depend  on  their 
molecular weight and the degree of deacetylation (DDA) of the parental material chitosan. This is 
affected by the distribution pattern of GlcN/GlcNAc along the oligomeric chain of CTS-OS [7–9]. In 
order  to  study  the  relationship  between  structure  and  biological  activity,  structurally  well-defined   
CTS-OS represent important factors to provide information regarding the development of enzymatic 
process with different enzymes that have different substrate specificity or cleavage patterns.   
There have been numerous reports studying the antitumor activity of chitosan and its derivatives 
which are chemically modified [10–14]. Among them, it is known that the antitumor mechanism of 
chitosan nanoparticles is related to its membrane-disrupting and apoptosis-inducing activities [15,16]. 
However antitumor mechanism of CTS-OS with different molecular weights and DDA are not well 
studied yet. Although it was suggested that lower molecular weight chitosan or water-soluble chitosan 
may have antitumor activities  in  clinical  use,  such effects  of them—including  of CTS-OS having 
different molecular weights and DDA—are as yet unproven. Therefore, structurally well-defined CTS-OS 
would represent important tools for investigating the antitumor effect of CTS-OS.   
In this study, we have attempted to develop a simple strategy for the preparation of more soluble 
forms of chitosan-oligosaccharides (CTS-OS) from the high-molecular weight chitosan (HMWC) and 
have investigated their structure and biological activities, especially on several tumor cell lines. For 
this purpose, CTS-OS were prepared by enzymatic digestion of HMWC and the relationship between 
their structures (molecular weights and DDA) and antitumor activities was examined against human 
PC3 (prostate cancer cell), human A549 (carcinomic human alveolar basal epithelial cell), and human 
HepG2 (hepatomacellular carcinoma) cells. 
2. Results and Discussion 
2.1. Gel-Filtration Chromatography of Chitosan Oligosaccharides   
The  chitosan-oligosaccharides  (CTS-OS)  in  the  supernatant  after  hydrolysis  of  HMWC  with  a 
chitosanase were recovered and lyophilized by the method described in the Materials and Methods to 
seek the feasibility of CTS-OS for the test of antitumor efficacy. CTS-OS was separated using an Int. J. Mol. Sci. 2011, 12                  
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ultrafiltration membrane filter with a molecular weight cut off (MWCO) of 10 kDa. The major product 
of CTS-OS was yielded at about 95 ±  0.05% after freeze drying. The major component of CTS-OS 
was found to be composed of, with different levels of DDA, dimer (18.8%), trimer (24.8%), tetramer 
(24.9%), pentamer (17.7%), hexamer (7.1%), heptamer (3.3%), and octamer (3.4%) (Table 1).   
Table 1. Preparation of chitosan oligosaccharides. 
Chitosan oligosaccharides  Yields(%)*  DDA (%)** 
Dimer  18.8  100 
Trimer  24.8  100 
Tetramer  24.9  100 
Pentamer  17.7  100 
Hexamer  7.1  833.3 
Heptamer  3.3  85.7 
Octamer  3.4  87.5 
*  The production yields of each oligosaccharide obtained by enzymatic hydrolysis of chitosan were 
calculated based on MALDI-TOF MS analysis data.   
**  DDA, degree of deacetylation of chitosan oligosaccharides. 
These results showed that the major component of CTS-OS derived from the enzymatic digestion of 
chitosan was identified to be (GlcN)n, n = 2–5, with yields of about 86 ±  0.2% after the freeze drying. 
CTS-OS was further then fractionated using a gel-filtration column chromatography (Figure 1). The 
carbohydrate positive fractions denoted F-1 (fractions 5–9) and F-2 (fraction 10–14) were pooled, 
dialyzed and freeze-dried. The two major carbohydrate-positive fractions obtained were applied to 
MALDI-TOF MS analysis, after which they were tentatively named chito-oligosaccharides (COS) and 
hetero-oligosaccharides (HOS). As shown in Table 1, DDA of CTS-OS obtained after the gel-filtration 
was determined to be in the range between 83.3 to 100%. Of these, COS was recovered over 86% from 
CTS-OS as fully deacetylated oligosaccharides by the gel-filtration column chromatography, which 
was shown to be a good approach for the separation of COS and HOS from CTS-OS with different 
DDA and molecular weights derived from the HMWC.   
Figure 1. Gel-filtration column chromatography of chitosan oligosaccharides (CTS-OS). 
CTS-OS were fractionated through a Bio P-4 gel-filtration column at ambient temperature. 
F-1, fractions 5-9; F-2, fractions 10–14.   
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2.2. MALDI-TOF MS Analysis 
Since the molecular weight and the degree of N-deacetylation of chitosan appeared to be key factors 
in  such  biological  activity,  MALDI-TOF  MS  analysis  was  conducted  to  determine  the  molecular 
weight and primary structure of F-1 and F-2. MALDI-TOF MS analysis showed that F-1 consisted of 
a mixture of (HOS)n, n = 6–15 (Figure 2A), while F-2 consisted of a mixture of (COS)n, n = 3–5 
(Figure 2B). F-2 contained about 67% (COS)n, n = 3–5 when compared to the relative percent intensity 
of the results obtained from the MALDI-TOF MS analysis of CTS-OS (Table 1). On the other hand, 
(HOS)n, n = 6–15 in F-1, which was detected in much lower quantity than (COS)n, n = 3–5 (Table 1), 
was obviously concentrated by Bio P-4 gel-filtration chromatography (Figure 2A). (COS)2 could not 
be separated through Bio P-4 gel filtration chromatography. The existence of different components of 
oligosaccharides  consisting  of  GlcN  and  GlcNAc  in  random  order  in  CTS-OS  indicated  that  the 
parental  HMWC is  partially deacetylated  chitosan.  Nevertheless, as  shown in  Figure 2B,  (COS)n, 
n = 3–5  in  F-2  obtained  from  the  gel  filtration  chromatography  was  the  major  component  of  the 
mixture of CTS-OS.   
Figure 2. Determination of the molecular mass and the degree of deacetylation of chitosan 
oligosaccharides.  The  chitosan  oligosaccharides,  F-1  (A)  and  F-2  (B),  obtained  after 
enzymatic digestion of chitosan (HMWC) and gel-filtration chromatography were analyzed 
by MALDI-TOF MS spectrometry. 
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As shown in Figure 2B, (COS)n, n = 6 was negligible in F-2; therefore, F-2 containing (COS)n, 
n = 3–5 and F-1 containing (HOS)n, n = 6–15 as major component (Table 2) were used as pure 
chito-oligosaccharide or hetero-oligosaccharide mixtures without further separation to investigate the 
antitumor  effect  on  human-derived  tumor  cells.  Thus,  the  antitumor  effects  of  HMWC,  CTS-OS, 
(COS)n,  n  =  3–5  and  (HOS)n,  n  =  6–15  on  tumor  cell  lines  were  investigated  to  evaluate  the 
relationship between the molecular weight and their DDA, as described in Tables 1 and 2, since no 
investigation  was  demonstrated  in  detail.  The  distribution  of  acetyl  groups  in  the  commercially 
available native chitosan is not evenly as in that produced by heterogeneous N-deacetylation of chitin. 
This is an interesting point for preparation of low molecular weight chitosan with different degrees of 
polymerization and DDA. Therefore, the preparation and characterization of the molecular weight and 
DDA of a series of CTS-OS precisely using MALDI-TOF MS gives rise to get better understanding of 
the relationship between biological functions of CTS-OS with different molecular weight and DDA. 
Table 2. Prediction of the molecular weight of chitosan oligosaccharides (CTS-OS) by 
MALDI-TOF MS analysis. 
Chitosan oligosaccharides (CTS-OS)  m/z 
(GlcN)n, n = 2–5  360, 524, 685, 846 
(GlcN)5 + GlcNAc  1049 
(GlcN)5 + GlcNAc + GlcN 
Or (GlcN)6 + GlcNAc 
1210 
(GlcN)5 + GlcNAc + (GlcN)2 
Or (GlcN)7 + GlcNAc 
1371 
(GlcN)5 + GlcNAc + (GlcN)2 + GlcNAc 
or (GlcN)7 + GlcNAc 
1574 
(GlcN)5 + GlcNAc + (GlcN)2 + GlcNAc + GlcN 
Or (GlcN)8 + (GlcNAc)2 
1735 
(GlcN)5 + GlcNAc + (GlcN)2 + GlcNAc + (GlcN)2 
Or (GlcN)9 + (GlcNAc)2 
1896 
(GlcN)5 + GlcNAc + (GlcN)2 + GlcNAc + (GlcN)2 + GlcNAc 
Or (GlcN)9 + (GlcNAc)3 
2099 
(GlcN)5 + GlcNAc + (GlcN)2 + GlcNAc + (GlcN)2 + GlcNAc + GlcN 
Or (GlcN)10 + (GlcNAc)3 
2260 
GlcN)5 + GlcNAc + (GlcN)2 + GlcNAc + (GlcN)2 + GlcNAc + (GlcN)2 
Or (GlcN)11 + (GlcNAc)3 
2421 
GlcN)5 + GlcNAc + (GlcN)2 + GlcNAc + (GlcN)2 + GlcNAc + (GlcN)2 + GlcNAc 
Or (GlcN)11 + (GlcNAc)4 
2625 
2.3. Antitumor Effect of High Molecular Weight Chitosan (HMWC)   
To examine the antitumor activity of HMWC, we carried out in vitro cytotoxicity experiments using 
MTT assay against human cells such as HepG2, A549, and PC3 as model tumor cell lines. Figure 3 
shows the relative cell viability of these cells following 24 h incubation with PBS as the control or a 
wide range of concentrations of HMWC with from 0.75 to 50 g∙mL
-1. While PBS alone did not show 
any appreciable toxicity, HMWC showed significantly higher cytotoxicity toward human HepG2 and Int. J. Mol. Sci. 2011, 12                  
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A549 than PC3 cells, with IC50 values lower than 50 g∙mL
-1. These results demonstrated that HMWC 
has antitumor activities against various tumor cell lines in vitro and is applicable as an antitumor agent 
based on the biodegradability and biocompatibility of HMWC, although the antitumor mechanism is 
not clear yet. Chitosan with different molecular weights and DDA are implicated to exhibit growth 
inhibitory effects against tumors in experimental animals, though the antitumor activity of chitosan 
seems to depend not only on molecular size but also on their chemical structure.   
Figure 3. Effect of high molecular weight chitosan (HMWC) on human tumor cell lines. 
Cytotoxicity of HMWC against human tumor cells was performed using MTT assay in 
vitro. Human PC3 (-◇-), human A549 (-■-) and human HepG2 (-▲-) cells were exposed to 
the indicated amounts of chitosan for 24 h. After 24 h incubation, the absorbance of the 
solution was measured at 575 nm using a micro-plate reader. Data are the means ±  standard 
deviation  of  three  different  experiments.  The  statistical  significance  of  the  difference 
between mean values was determined by the student’s t-test. *P < 0.05 and **P < 0.1 was 
considered significant. Experiments were performed at least in triplicates. 
 
2.4. Antitumor Effect of HMWC, CTS-OS, COS and HOS on Human PC3 Cells 
The antitumor effects  of  CTS-OS, COS  and HOS  on  human PC3  cells  were evaluated  in  vitro 
cytotoxicity experiment with a wide range of concentrations from 0.75 to 50 g∙mL
-1, as described 
above. Figure 4 shows that CTS-OS showed the strongest effect against human PC3 cells used as a 
model cell line, with CC50 values of g∙mL
-1. Treatment of COS could inhibit tumor growth similar 
to that of CTS-OS. In contrast, as shown in Figure 3, HOS showed slightly less growth inhibition of 
tumor cells with the 50% cytotoxic concentration (CC50) values of 50 g∙mL
-1. Compared to HMWC, 
HOS  showed  no  apparent  difference  in  antitumor  activity,  though  native  chitosan  and  HOS  have 
different extent of sizes of molecular weight. Therefore, DDA is considered as a principal features of 
HMWC,  CTS-OS  and  COS.  Unlike  HMWC,  both  CTS-OS  and  COS  attract  greater  interest  as 
antitumor agents due to their water solubility. Int. J. Mol. Sci. 2011, 12                  
     
272 
Figure  4.  Effect  of  HMWC,  CTS-OS,  COS  and  HOS  on  human  PC3  cells.  Cells 
were exposed to the indicated amounts of HMWC (-X-), CTS-OS (-■-), HOS (-◆-), and COS 
(-▲-) for 24 h. After 24 h incubation, cytotoxicity of CTS-OS, COS and HOS against 
tumor cells was determined by MTT assay. Data are mean values calculated from three 
independent experiments (± SD). *P < 0.05 and **P < 0.1 was considered significant.   
 
2.5. Antitumor Effect of HMWC, CTS-OS, COS and HOS on Human A549 Cells 
The results showed that antitumor effects of CTS-OS, COS and HOS on human A549 cells were 
observed  from  in  vitro  cytotoxicity experiment  with  a wide range of concentrations  from  0.75 to 
50 g∙mL
-1, as  described above.  Figure 5 shows  that  CTS-OS, which  consists of COS  and HOS, 
displayed the strongest effect toward A549 cells with CC50 values of 25 g∙mL
-1. Treatment of COS 
could inhibit tumor growth similar to that observed by CTS-OS as well. On the other hand, HOS 
showed much low activity against tumor cells with CC50 values higher than 50 g∙mL
-1. No apparent 
difference of the antitumor activity of HOS compared to that of HMWC was observed.   
2.6. Antitumor Effect of HMWC, CTS-OS, COS and HOS on Human HepG2 Cells 
The antitumor effects of CTS-OS, COS and HOS on human HepG2 cells were evaluated in vitro 
cytotoxicity experiments with a wide range of concentrations from 0.75 to 50 g∙mL
-1. The results 
showed  that  CTS-OS has  the  strongest  effect  against  HepG2  cells  with  CC50  values  lower  than 
25 g∙mL
-1 (Figure 6). Treatment of a series of CTS-OS COS and HOS on HepG2 cells resulted in 
apparent toxicity compared with the other cell lines, A549 and PC3 cells (Figures 4 and 5). These 
results  suggest  that  chitosan  oligosaccharides  have  higher  specificity  toward  human  HepG2  cells, 
while there was slightly increased (<15%) relative cell viability to both cells A549 and PC3 cells. On 
the other hand, treatment of COS could inhibit tumor growth similar to the relative cell viability of all 
three cells exposed to CTS-OS at the same concentration. As expected, HOS showed much less tumor 
cell growth inhibition with CC50 values higher than 50 g∙mL
-1. However, compared to HMWC, HOS 
showed similar antitumor activity. Int. J. Mol. Sci. 2011, 12                  
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Figure  5.  Effect  of  HMWC,  CTS-OS,  COS  and  HOS  on  human  A549  cells.  Cells 
were exposed to the indicated amounts of HMWC (-X-), CTS-OS (-■-), HOS (-◆-), and 
COS (-▲-) for 24 h. After 24 h incubation, cytotoxicity of CTS-OS, COS and HOS against 
tumor cells was determined by MTT assay. Data are mean values calculated from three 
independent experiments (± SD). *P < 0.05 and **P < 0.1 was considered significant.   
 
Figure 6. Effect of HMWC, CTS-OS, COS and HOS on human HepG2 cells. HepG2 cells 
were exposed to the indicated amounts of HMWC (-X-), CTS-OS (-■-), HOS (-◆-), and 
COS (-▲-) for 24 h. After 24 h incubation, cytotoxicity of HMWC, CTS-OS, HOS and 
COS  against tumor cells  was  examined by MTT assay. Data expressed  are the means 
(± SD) of three different experiments. *P < 0.05 and * P < 0.1 was considered significant.   
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The functional properties of chitosan and its depolymerized compounds are mainly dependent upon 
their  solubility,  molecular  weight  and  DDA  in  aqueous  media.  To  overcome  these  problems, 
preparation of chitosan oligosaccharides in an active form is obviously gaining importance in many 
biomedical applications. Although several methods are available for the preparation of oligomeric 
compounds, development of new effective methods for producing biologically active molecules from 
chitosan is a major challenge in carbohydrate chemistry to provide sufficient amounts of products 
needed for fundamental research and their potential application in various fields. Therefore, the main 
objective of the present study was to evaluate the structural characteristics such as molecular weight 
and DDA of COS and HOS obtained from the enzymatic hydrolysis of HMWC, and their antitumor 
activity toward human tumor cells was tested in this study. The results clearly demonstrated that the 
molecular  weight  and  DDA  of  chitosan  oligosaccharides  are  important  factors  for  their  antitumor 
activities (Table 3). The relatively smaller size (molecular weight), higher solubility, and the lower 
degree of deacetylation (DDA) of CTS-OS and COS than HMWC would be promising factors for the 
development of potential pharmaceuticals or neutraceuticals using these chitosan derivatives.   
Table  3.  Effect  of  the  degree  of  deacetylation  (DDA)  of  chitosan  derivatives  on   
antitumor activity.   
Samples  DDA (%) 
CC50 (µg∙mL
-1)* 
PC3  A549  HepG2 
HMWC  98.5  50  50  50 
CTS-OS  98.5  25  25  25 
COS  100  25  5  12.5 
HOS  85.5  50  50  50 
* CC50 (g∙mL
-1) the concentration of each sample required for 50% cell death. 
3. Experimental Section 
3.1. Materials 
A high molecular weight of chitosan (HMWC) with approximately 1,900 kDa, 98.5% degree of 
deacetylation  (DDA)  was  kindly  provided  by  Prof.  R.  D.  Park,  Cheonnam  University,  Korea.  A 
recombinant chitosanase (OHK) was purchased from Kyowa Chemical Ltd. (Japan). All other reagents 
were used without further purification and were of the highest grade available. 
3.2. Tumor Cell-Lines 
Human PC3 (prostate cancer cell, ATCC No. CRL-1435
TM), A549 (carcinomic human alveolar 
basal epithelial cell, ATCC No. CCL-185
TM) and HepG2 (hepatocellular carcinoma cell, ATCC No. 
HB-8065
TM) cells are used as the first choice for evaluating the antitumor effects of chitosan and its 
oligosaccharides  in  vitro.  Cells  were  grown  and  maintained  in  Roswell  Park  Memorial  Institute 
medium (RPMI) 1640 supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS) and 1% 
penicillin-streptomycin (GIBCO, USA). The cells were maintained at 37 
oC under 5% CO2.   Int. J. Mol. Sci. 2011, 12                  
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3.3. Preparation of Chitosan-Oligosaccharides 
The high molecular weight chitosan (HMWC) was fully dissolved in 1% acetic acid to be 1% (w/v) 
at room temperature and the pH of the solution was adjusted to pH 5.0 with NaHCO3. The chitosan 
solution was centrifuged at 14,000 rpm for 30 min to remove insoluble materials. Then chitosan was 
hydrolyzed at 30 ° C for 2 h using 0.5 U (nmol reducing sugars/g/min) of recombinant chitosanase 
OHK purchased from Kyowa Chemical Ltd., and the reactant was boiled to quench the reaction at   
100 
oC  for  10  min.  Following,  an  ultra-filtration  membrane  filter  with  molecular  weight  cut  off 
(MWCO)  of  10  kDa  was  used  to  remove  denatured  protein,  insoluble  materials  and  separate   
water-soluble chitosan-oligosaccharides CTS-OS. Obtained CTS-OS was further free-dried, and kept 
at 4 
oC until use. For cytotoxicity test against tumor cells, solutions (1% acetic acid) of HMWC and its 
enzyme hydrolyzed products (CTS-OS, HOS, and COS) were adjusted to pH 5.0 with 1 M NaHCO3 
and then applied to each tumor cell culture. 
3.4. Gel-filtration Chromatography 
CTS-OS obtained after digestion of HMWC was further fractionated using a gel-filtration column 
chromatograph (Ф 1.0 cm ×  L 30 cm) packed with Bio Gel-P 4 (Bio-RAD, USA) gel, which had been 
pre-equilibrated with a volatile buffer consisting of ammonia/formic acid (pH 7.5). A total of 500 mg 
CTS-OS dissolved in 1.0 mL of the same buffer was applied to a gel-filtration column and eluted at a 
flow-rate of 5 μL per min until no carbohydrates were detected using the Nelson-Somogyi method [17].   
3.5. Determination of Molecular Weight and Deacetylation Degree (DDA) of CTS-OS by MALDI-TOF 
MS Analysis   
The  two  major  carbohydrate-positive  fractions  obtained  were  applied  to  matrix-assisted  laser 
desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS) analysis. The molecular 
weight  and  deacetylation  degree  (DDA)  of  CTS-OS  obtained  from  the  enzymatic  hydrolysis  of 
chitosan  was  determined  by  matrix-assisted  laser  desorption/ionization-mass  spectrometry   
(MALDI-TOF MS) analysis (Voyager-DE TM STR Biospectrometry Workstation, Applied Biosystems 
Inc.,  NCIRF,  Korea).  The  molecular  weight  and  DDA  of  CTS-OS  was  calculated  based  on the 
molecular weight of glucosamine (GlcN) and N-acetylglucosamine (GlcNAc). 
3.6. Cytotoxicity against Tumor Cells in Vitro 
The viability of tumor cell lines PC3, A549, and HepG2 human-derived against HMWC and its 
oligosaccharides was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
(MTT, Sigma) reduction assay [18].
 Tumor cells were placed in RPMI 1640 supplemented with 10% 
FBS (PAA) and 1% penicillin-streptomycin (GIBCO) at 1 ×  10
4 cells/well in 24-well culture plates. 
After, the cells were cultured overnight at 30 
oC, and the medium was changed to fresh RPMI 1640. 
Then cells were exposed to the indicated amounts of chitosan and its oligosaccharides for 24 h. After 
monolayer cultivation for 24 h, the medium was removed and 100 μL of the maintenance medium 
(MM) and different concentrations of samples were added to each well and the samples were then 
incubated for an additional 24 h. After 24 h incubation, 20 µL of MTT ((3,4,5-dimetylthiazol-2-yl)-2,5-Int. J. Mol. Sci. 2011, 12                  
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diphenyl  tetrazonium  bromide))  solution  (5  mg∙mL
-1)  was  added  to  each  well  of  the  plate  and   
re-incubated for 4 h. After removal of the supernatant, 100 µL of DMSO were added to each well to 
dissolve the crystals completely and the absorbance was measured at 570 nm using an ELISA Reader 
(Bio-Rad,  USA).  The  cytotoxicity  was  expressed  as  the  50%  cytotoxic  concentration  (CC50),  the 
concentration of samples needed to inhibit the cell growth by 50%.   
3.7. Statistical Analysis 
All data were expressed as the means ±  standard Deviation (SD), which are representative of at 
least three different experiments. Comparison between individual data points of each experiment were 
conducted using Student’s t-test. All p-values of <0.1 were considered to be significant. 
4. Conclusions 
In the present study, we report antitumor effects of HMWC, CTS-OS, COS and HOS toward three 
different human tumor cell lines used as a model for the experiments in vitro. Our results show that, 
among  other  compounds,  CTS-OS  and  COS  obtained  from  enzymatic  hydrolysis  of  chitosan  and 
identified by MALDI-TOF MS analysis showed significant antitumor activities against human A549, 
PC3, and HepG2 tumor cells. More importantly, no significant antitumor effect of HMWC and HOS 
was observed. Taken together, these results strongly suggest that properties of chitosan, such as the 
average molecular weight and the degree of N-deacetylation (DDA), might be important factors for the 
exhibition of antitumor activity in vitro. Since CTS-OS and COS have higher solubility in water and 
narrow molecular weight distribution ensuring reproducible pharmacological properties compared to 
HOS and HMWC, they may provide valuable information for the further development of antitumor 
agents deriving from chitosan.   
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